amantadine and Weight Gain studies

amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source

Research Excerpts

Excerpt	Relevance	Reference
"Outpatients with schizophrenia or schizoaffective disorder (DSM-IV-TR criteria) were randomly assigned to olanzapine alone (n = 50), olanzapine plus algorithm A (olanzapine + A [amantadine 200 mg/d with possible switches to metformin 1,000-1,500 mg/d and then to zonisamide 100-400 mg/d; n = 76]), or olanzapine plus algorithm B (olanzapine + B [metformin 1,000-1,500 mg/d with possible switches to amantadine 200 mg/d and then to zonisamide 100-400 mg/d; n = 73])."	9.16	Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. ( Case, M; Hoffmann, VP; Jacobson, JG, 2012)
"Patients with schizophrenia (Sch), schizoaffective, schizophreniform, or bipolar (BP) I disorders [Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)]; not manic or acutely psychotic [Brief Psychiatric Rating Scale (BPRS) total score < or =45]; treated with olanzapine for 1-24 months; and who had gained > or =5% of their initial body weight were examined to determine whether amantadine could attenuate weight gain or promote weight loss."	9.11	Amantadine for weight gain associated with olanzapine treatment. ( Breier, A; Bymaster, FP; Carlson, CD; Cavazzoni, PA; Deberdt, W; Floris, M; Trzaskoma, QN; Wiener, K; Winokur, A, 2005)
" Amantadine (100-300 mg/day) was started in 12 patients having a mean weight gain of 7."	9.09	Effect of amantadine on weight gain during olanzapine treatment. ( Deberdt, W; Floris, M; Lejeune, J, 2001)
"According to this meta-analysis of 5 RCTs, adjunctive amantadine seems to be an effective option for attenuating antipsychotic-related weight gain in patients with schizophrenia."	8.95	Amantadine for Antipsychotic-Related Weight Gain: Meta-Analysis of Randomized Placebo-Controlled Trials. ( Gu, YH; Li, M; Ng, CH; Ungvari, GS; Wang, S; Xiang, YQ; Xiang, YT; Yang, XH; Zheng, W, 2017)
"The purpose of this study was to explore whether amantadine would slow or reverse significant weight gain in children and adolescents treated with antipsychotics and/or mood stabilizers that may promote increases in weight."	7.71	Amantadine treatment of psychotropic-induced weight gain in children and adolescents: case series. ( Gracious, BL; Krysiak, TE; Youngstrom, EA, 2002)
"Outpatients with schizophrenia or schizoaffective disorder (DSM-IV-TR criteria) were randomly assigned to olanzapine alone (n = 50), olanzapine plus algorithm A (olanzapine + A [amantadine 200 mg/d with possible switches to metformin 1,000-1,500 mg/d and then to zonisamide 100-400 mg/d; n = 76]), or olanzapine plus algorithm B (olanzapine + B [metformin 1,000-1,500 mg/d with possible switches to amantadine 200 mg/d and then to zonisamide 100-400 mg/d; n = 73])."	5.16	Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. ( Case, M; Hoffmann, VP; Jacobson, JG, 2012)
"Patients with schizophrenia (Sch), schizoaffective, schizophreniform, or bipolar (BP) I disorders [Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)]; not manic or acutely psychotic [Brief Psychiatric Rating Scale (BPRS) total score < or =45]; treated with olanzapine for 1-24 months; and who had gained > or =5% of their initial body weight were examined to determine whether amantadine could attenuate weight gain or promote weight loss."	5.11	Amantadine for weight gain associated with olanzapine treatment. ( Breier, A; Bymaster, FP; Carlson, CD; Cavazzoni, PA; Deberdt, W; Floris, M; Trzaskoma, QN; Wiener, K; Winokur, A, 2005)
" Amantadine (100-300 mg/day) was started in 12 patients having a mean weight gain of 7."	5.09	Effect of amantadine on weight gain during olanzapine treatment. ( Deberdt, W; Floris, M; Lejeune, J, 2001)
"According to this meta-analysis of 5 RCTs, adjunctive amantadine seems to be an effective option for attenuating antipsychotic-related weight gain in patients with schizophrenia."	4.95	Amantadine for Antipsychotic-Related Weight Gain: Meta-Analysis of Randomized Placebo-Controlled Trials. ( Gu, YH; Li, M; Ng, CH; Ungvari, GS; Wang, S; Xiang, YQ; Xiang, YT; Yang, XH; Zheng, W, 2017)
" Included were 158 patients with schizophrenia or bipolar disorder and a body mass index (BMI) > or = 25 kg/m2 who had received olanzapine treatment in combination with nizatidine (n = 68), sibutramine (n = 42), or amantadine (n = 48)."	3.75	Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis. ( Heinloth, AN; Hoffmann, VP; Kinon, BJ; Lipkovich, I; McGregor, HS; Stauffer, VL, 2009)
"The purpose of this study was to explore whether amantadine would slow or reverse significant weight gain in children and adolescents treated with antipsychotics and/or mood stabilizers that may promote increases in weight."	3.71	Amantadine treatment of psychotropic-induced weight gain in children and adolescents: case series. ( Gracious, BL; Krysiak, TE; Youngstrom, EA, 2002)
"Obesity is associated with considerable morbidity and decreased life expectancy."	2.41	Options for pharmacological management of obesity in patients treated with atypical antipsychotics. ( Sanders, TA; Taylor, D; Werneke, U, 2002)

Research

Studies (7)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Change From Baseline to Endpoint in Weight

Change From Baseline to Endpoint in Brief Psychiatric Rating Scale (BPRS) Total Score

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (71.43)	29.6817
2010's	2 (28.57)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Zheng, W	1
Wang, S	1
Ungvari, GS	1
Ng, CH	1
Yang, XH	1
Gu, YH	1
Li, M	1
Xiang, YQ	1
Xiang, YT	1
Stauffer, VL	1
Lipkovich, I	1
Hoffmann, VP	2
Heinloth, AN	1
McGregor, HS	1
Kinon, BJ	1
Case, M	1
Jacobson, JG	1
Werneke, U	1
Taylor, D	1
Sanders, TA	1
Gracious, BL	1
Krysiak, TE	1
Youngstrom, EA	1
Deberdt, W	2
Winokur, A	1
Cavazzoni, PA	1
Trzaskoma, QN	1
Carlson, CD	1
Bymaster, FP	1
Wiener, K	1
Floris, M	2
Breier, A	1
Lejeune, J	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Assessment of the Safety, Efficacy, and Practicality of an Algorithm Including Amantadine, Metformin and Zonisamide for the Prevention of Olanzapine-Associated Weight Gain in Outpatients With Schizophrenia[NCT00401973]	Phase 3	199 participants (Actual)	Interventional	2006-11-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	kilograms (Least Squares Mean)
Olanzapine	2.76
Olanzapine + Amantadine	2.40
Olanzapine + Metformin	0.65

The BPRS is an 18-item clinician-administered scale used to assess the degree of severity of a subject's general psychopathological symptoms. Each item is rated on a scale from 1 (symptom not present) to 7 (symptom extremely severe). The BPRS total score ranges from 18 to 126. (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

Change From Baseline to Endpoint in Clinical Global Impression - Severity Scale (CGI-S)

Intervention	units on a scale (Mean)
	Baseline	Change from Baseline
Olanzapine	48.24	-13.89
Olanzapine + Amantadine	45.90	-9.90
Olanzapine + Metformin	47.00	-9.72

Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

Intervention	units on a scale (Mean)
	Baseline	Change from Baseline
Olanzapine	4.06	-0.98
Olanzapine + Amantadine	4.03	-0.72
Olanzapine + Metformin	4.00	-0.79

The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

Correlations Between Weight Changes and Changes in Eating Inventory (EI) and Food Craving Inventory (FCI) at 2 Weeks and 22 Weeks

Intervention	units on a scale (Mean)
	Baseline	Change from Baseline
Olanzapine	12.76	-6.39
Olanzapine + Amantadine	14.22	-4.12
Olanzapine + Metformin	15.40	-4.36

To understand the drivers of weight gain as indicated by the correlation between weight changes and changes in the Eating Inventory (EI) and Food Craving Inventory (FCI). The EI is a 51-item inventory that measures dietary restraint, disinhibition, and perceived hunger. The FCI is a 28-item instrument measuring the frequency over the past month of general cravings and cravings for specific types of foods, namely: high fats, sweets, carbohydrates/starches, and fast-food fats. Correlations were computed on the combined treatment groups. (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

Intervention	correlation (Number)
	EI: Disinhibition	EI: Cognitive Restraint	EI: Hunger	FCI: Carbohydrates/Starches (N=186, N=141)	FCI: Fast Food Fats (N=188, N=140)	FCI: High Fats (N=186, N=138)	FCI: Sweets (N=187, N=140)	FCI: Total Score (N=184, N=137)
2 Weeks	-0.034	-0.273	-0.150	0.013	-0.019	0.051	0.022	0.039
22 Weeks	0.285	-0.038	0.148	-0.064	0.047	0.043	-0.008	-0.000

Intervention	millimole per Liter (mmol/L) (Mean)
	Baseline	Change from Baseline
Olanzapine	5.32	0.26
Olanzapine + Amantadine	5.25	0.10
Olanzapine + Metformin	5.28	0.01

Intervention	millimole per liter (mmol/L) (Mean)
	Baseline	Change from Baseline
Olanzapine	1.25	-0.00
Olanzapine + Amantadine	1.26	-0.11
Olanzapine + Metformin	1.22	-0.08

Intervention	millimole per Liter (mmol/L) (Mean)
	Baseline	Change from Baseline
Olanzapine	3.02	0.16
Olanzapine + Amantadine	3.06	-0.04
Olanzapine + Metformin	2.91	-0.02

Intervention	millimole per Liter (mmol/L) (Mean)
	Baseline	Change from Baseline
Olanzapine	5.01	0.36
Olanzapine + Amantadine	5.03	0.01
Olanzapine + Metformin	4.91	-0.08

amantadine and Weight Gain

Research Excerpts

Research

Studies (7)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Change From Baseline to Endpoint in Weight

Change From Baseline to Endpoint in Brief Psychiatric Rating Scale (BPRS) Total Score

Change From Baseline to Endpoint in Clinical Global Impression - Severity Scale (CGI-S)

Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

Correlations Between Weight Changes and Changes in Eating Inventory (EI) and Food Craving Inventory (FCI) at 2 Weeks and 22 Weeks

Mean Change From Baseline to Endpoint in Fasting Glucose

Mean Change From Baseline to Endpoint in Fasting High Density Lipoprotein (HDL) Cholesterol

Mean Change From Baseline to Endpoint in Fasting Low Density Lipoprotein (LDL) Cholesterol

Mean Change From Baseline to Endpoint in Fasting Total Cholesterol

Mean Change From Baseline to Endpoint in Fasting Triglycerides

Mean Change From Baseline to Endpoint in Hemoglobin A1c

Reviews

Trials

Other Studies

Article	Year
Amantadine for Antipsychotic-Related Weight Gain: Meta-Analysis of Randomized Placebo-Controlled Trials. Journal of clinical psychopharmacology, 2017, Volume: 37, Issue:3 Topics: Amantadine; Antipsychotic Agents; Dopamine Agents; Drug Therapy, Combination; Drug-Related Side Effe	2017
Options for pharmacological management of obesity in patients treated with atypical antipsychotics. International clinical psychopharmacology, 2002, Volume: 17, Issue:4 Topics: Amantadine; Antipsychotic Agents; Cimetidine; Cyclobutanes; Fluoxetine; Fructose; Humans; Lactones;	2002

Article	Year
Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. The Journal of clinical psychiatry, 2012, Volume: 73, Issue:2 Topics: Adolescent; Adult; Aged; Algorithms; Amantadine; Antipsychotic Agents; Benzodiazepines; Clinical Pro	2012
Amantadine for weight gain associated with olanzapine treatment. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2005, Volume: 15, Issue:1 Topics: Adolescent; Adult; Aged; Amantadine; Analysis of Variance; Antiparkinson Agents; Antipsychotic Agent	2005
Effect of amantadine on weight gain during olanzapine treatment. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2001, Volume: 11, Issue:2 Topics: Adult; Amantadine; Antipsychotic Agents; Benzodiazepines; Dopamine Agents; Female; Humans; Male; Ola	2001

Article	Year
Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis. BMC psychiatry, 2009, Mar-28, Volume: 9 Topics: Adult; Amantadine; Appetite; Benzodiazepines; Bipolar Disorder; Cognition Disorders; Cyclobutanes; D	2009
Amantadine treatment of psychotropic-induced weight gain in children and adolescents: case series. Journal of child and adolescent psychopharmacology, 2002,Fall, Volume: 12, Issue:3 Topics: Adolescent; Amantadine; Analysis of Variance; Child; Female; Humans; Male; Mental Disorders; Psychot	2002